The State of Kerala was formed on 1st November 1956 consequent on the Reorganisation of States. It comprises the former Travancore-Cochin State (except the present Kanyakumari District and Shencottah Taluk of the present Tamil Nadu) and the Malabar District and the Kasargod Taluk of South Kanara District of the then composite Madras State.

Indian Institute of Science Education and Research Bhopal was created in 2008 by the Ministry of Human Resource Development, Government of India. Its mission is to provide quality science education to UG and PG students. The prime focus is to integrate science education and research with a motive of attracting bright students and world class faculty. The Institute is committed to impart high moral and ethical values and create concern for social and environment awareness.

About Authors: Aswini K. Reddy, Swetha Yasa, Srivally Challa, Masoom. md
Mallareddy Institute of Pharmaceutical Sciences, Hyderabad

ABSTRACT
Both solid- and liquid-phase combinatorial chemistry have emerged as powerful tools for identifying pharmacologically active compounds and optimizing the biological activity of a lead compound. Complementary high-throughput in vitro assays are essential for compound evaluation. Cell-based assays that use optical endpoints permit investigation of a wide variety of functional properties of these compounds including specific intracellular biochemical pathways, protein-protein interactions, and the subcellular localization of targets. Integration of combinatorial chemistry with contemporary pharmacology now represents an important factor in drug discovery and development.

This is an exceptionally exciting time in the field of pharmacology. The environment for the identification of new therapeutic targets and agents that interact with these targets has rapidly changed with the application of genetic tools and genomics. Extrapolation from the genomic sequencing of lower organisms suggests that there will be a 10-fold increase in the number of potential human therapeutic targets in the next several years with the completion of the Human Genome Project (Drews, 1996). This is leading to a fundamental transformation in pharmacology; no longer is there a dearth of molecular targets for small molecules. Rather, the emphasis is now on validating whether or not the targets are appropriate for therapeutic intervention, on generating large arrays of compounds that represent diverse portions of “chemical space”, and developing methods to quickly assess the credentials of small molecules as target disrupters. We believe many of the tools and reagents that are being developed to facilitate this scientific activity will emerge as vital for future academic pharmacological research. Perhaps most important will be the exploitation of combinatorial chemistry libraries, which are becoming widely available. Although we cannot comprehensively review this broad topic here, the goal of this brief commentary is to portray some of the strategies and potentials of combinatorial chemistry libraries as they relate to pharmacological studies.

The history of Jamia Hamdard begins with the establishment of a small Unani clinic in the year 1906 by Hakeem Hafiz Abdul Majeed, one of the well-known practitioners of Unani System of Medicine of his time. Hakeem Hafiz Abdul Majeed had a vision of making the practice of Unani Medicine into a scientific discipline so that Unani medicines could be dispensed in a more efficacious manner to patients. He gave the name "Hamdard" to his venture which means "sympathy for all and sharing of pain".

ONGC ranks as the Numero Uno Oil & Gas Exploration & Production (E&P) Company in the world, as per Platts 250 Global Energy Companies List for the year 2008 based on assets, revenues, profits and return on invested capital (ROIC).
ONGC ranks 20th among the Global publicly-listed Energy companies as per ‘PFC Energy 50”

Institute of Genomics & Integrative Biology (IGIB), one of the premier constituent establishments of Council of Scientific and Industrial Research (CSIR), is carrying out research and development in the areas of genomics, molecular medicines, bioinformatics and environmental biotechnology. The Institute has played pivotal role in genomics and integrative biology through R & D partnerships and in collaboration with medical institutes, universities and the industry.

Banaras Hindu University ranks among the first few in the country in the field of academic and research output. This university has two campuses, 3 institutes, 16 faculties, 140 departments, 4 advanced centers and 4 interdisciplinary schools.

About Authors: Shoeib Afroz Mohammad,
M.Pharm (Pharmacology),
Vaagdevi College of Pharmacy, Kakatiya University

Reference ID: PHARMATUTOR-ART-1087

BACKGROUND:
By the 1930s, scientists had isolated and determined the structure of the steroid hormones and found that high doses of androgens, estrogens or progesterone inhibited ovulation. The first oral-contraceptive formulations marketed in the United States, in 1960 and1961, contained 2 to 5 times as much estrogen and 5 to 10 times as much progestin as the oral contraceptives now in use. Since introduced in May of 1960, these pills have provided reliable contracep¬tion for millions of woman throughout the world.They were given in a regimen consisting of 21 active tablets containing estrogen and progestin followed by 7 days of placebo tablets (21/7 regimen). The 7 days of placebo was designed for menses to occur during that time. The use of these high-dose formulations was linked to increased risks of ischemic stroke, myocardial infarction, and pulmonary embolism in healthy young women. The estrogen and progestin were reduced rapidly during the 1960s and 1970s because of concern about safety and because the reduction of the doses did not reduce the contraceptive effectiveness.The reductions in the dose of estrogen are believed to have decreased the risk of venous thrombosis. The combination estrogen–progestin oral contraceptives that are now on the market contain estrogen at doses ranging from 20 to 50 μg of ethinyl estradiol or, uncommonly, mestranol. Currently there are over 70 different brands on the market. 1

Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia.

National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as an ‘Institute of National Importance’.

NBRI is a premier plant based multidisciplinary, state-of-art national R&D Centre of CSIR undertaking research from classical taxonomy to cutting edge areas of modern biology-including both applied and basic research in the fields of biochemistry, bioinformatics, biotechnology, conservation biology, cytogenetics, environmental sciences, ethnopharmacology, floriculture, microbiology, molecular biology and genetic engineering, pharmacognosy, pharmacy, physiology, phytochemistry, plant biodiversity,  plant breeding, taxonomy and

Akumentis have strong back up of world class manufacturing & R&D facilities. The manufacturing facility is 3rd largest in Asia with WHO GMP, ISO 9001, ISO14001, USFDA & UKHMRA certifications. we have 1000 innovative products in pipeline.

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Aayushi Pharmaceuticals Pvt. Ltd., has been involved in contract manufacturing of pharmaceutical oral liquid formulations with a vision of providing quality products to the society .Our manufacturing unit is located in Chhatral GIDC, Gujarat , 35 kms from Ahmadabad. We have a team of fully dedicated and experienced professionals who provide each business partner with high quality products, timely deliveries, conforming to WHO standards.

Akumentis have strong back up of world class manufacturing & R&D facilities. The manufacturing facility is 3rd largest in Asia with WHO GMP, ISO 9001, ISO14001, USFDA & UKHMRA certifications. we have 1000 innovative products in pipeline.